Pancreatic Cancer
Conditions
Brief summary
Systemic chemotherapy can improve disease-related symptoms and/or prolong survival in patients with pancreatic cancer. Before the start of chemotherapy, the diagnosis pancreatic carcinoma must be confirmed by tumor tissue samples, which are often obtained during endoscopic ultrasound (EUS) by fine needle aspiration (FNA) or fine needle biopsy (FNB). Obtaining core biopsies by FNB has several potential benefits, such as making a more reliable diagnosis, performing immunohistochemistry for diagnostic reasons and in the future obtaining enough malignant cells to deliver personalized based chemotherapy regimen based on mutations detected by next generation sequencing. Obtaining high quality and sufficient tumor material is essential for genomic profiling with a preference of FNB over FNA. Up to now, no specific FNB needle has been found to be superior in diagnostic accuracy and in obtaining tissue for genomic profiling. In this study, we aim to evaluate the diagnostic accuracy of a new FNB needle (Micro-Tech Europe GmbH, Düsseldorf, Germany) and we study the adequacy of the obtained tissue samples for performing genetic sequencing.
Detailed description
This study is an international multicenter prospective cohort study. The study will be performed in collaboration with the disciplines of Gastroenterology and Pathology of the participating hospitals.
Interventions
None listed
Sponsors
Radboud University Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18 years and older * Clinical suspicion of pancreatic adenocarcinoma * Indication for obtaining EUS-guided histology of a suspected pancreatic lesion * Written informed consent
Exclusion criteria
* Contra-indications to undergoing an EUS (e.g., oropharyngeal abnormalities) * Altered anatomy (e.g., after previous Whipple-operation, Roux-and-Y gastrojejunostomy) * Contra-indications to the administration of benzodiazepines, propophol or opioids * Pregnancy * Insufficient knowledge of the Dutch language to be able to understand the patient information
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic accuracy of the Micro-Tech FNB needle in obtaining pancreatic malignancy | 2 years | Pathologist scores the obtained specimen according the Bethesda system. Diagnostic accuracy will be quantified by the sensitivity and specificity and expressed as frequency of pancreatic malignancy as confirmed by histological evaluation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Ability to perform genetic sequencing on the sample | 2 years | Pathologist will analyze the obtained specimen and determines the size and tumor cellularity. The specimen is deemed sufficient for performing genetic sequencing when tumor cellularity is \>20% and the surface is \>5mm2. At this stage, no genetic sequencing will be performed |
| Puncture success rate | 2 years | Puncture is successful if the pathologist is able to make a diagnosis on the obtained specimen. By putting each biopsy in a different formalin jar, we can count how many biopsies are needed to be taken to obtain a representative biopsy for diagnosis. |
| User experience | 2 years | User experience of performing FNB with this needle scored with a questionnaire filled in by each participating gastroenterologist after performing all procedures. |
Countries
Netherlands
Contacts
PRINCIPAL_INVESTIGATORErwin van Geenen, MD, PhD
Radboud University Medical Center
Outcome results
None listed